A prospective case–control trial to evaluate and compare the efficacy and safety of atosiban versus placebo in In vitro Fertilization-embryo transfer program

Mishra, Vineet; Agarwal, Himani; Goel, Sandeep; Roy, Priyankur; Choudhary, Sumesh; Lamba, Sunita

doi:10.4103/jhrs.jhrs_7_17

Cited by 6 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of the operation is determined by the frequency of uterine contractions, the receptivity of the endometrium, and the quality of the embryos transplanted. According to research, the uterine contractility evaluated before embryo transfer (ET) in IVF cycles is six times greater than that recorded before ovulation in natural cycles [5] . Excessive manipulation of the cervix, such as the use of tenaculum, may potentially produce uterine contractions, so preventing embryo implantation.…”

Section: Discussionmentioning

confidence: 99%

Effect of administration of atosiban at day of embryo transfer on in-vitro fertilization out come

Kadhim¹,

Salman²,

Jwad³

2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

Background:The most crucial step of assisted reproduction is embryo implantation, which is impacted by a variety of factors, including the patient's age, embryo quality, and endometrial receptivity. The embryo transfer (ET) procedure, which induces uterine contractions, may hinder embryo implantation. Objectives: On the day of embryo transfer, examine the effects of Atosiban administration on implantation, clinical pregnancy, miscarriage, and live birth rates. Material and Methods:The study included 60 individuals with a diagnosis of primary or secondary infertility due to male or female factor, tubal factors, moderate endometriosis, or other unknown reasons. Two groups of patients were selected at random. The first group received 6.75 milligrammes of atosiban intravenously 30 minutes before ET, whereas the second group received no medication. Pregnancy outcomes in both groups were compared. Results: Significantly higher clinical pregnancy and implantation rates were observed (60% versus 30%) and (37.8% versus 17.8%) respectively, with non-significantly higher live birth rates (94.4% versus 66.7%), while the miscarriage rate was lower in the Atosiban group but not significantly (5.6% versus 33.3%). Conclusion: These findings imply that atosiban therapy prior to embryo transfer improves embryo implantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of administration of atosiban at day of embryo transfer on in-vitro fertilization out come

Kadhim¹,

Salman²,

Jwad³

2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

show abstract

“…Many issues were associated with the outcome of IVF-ET, among which the uterine contractions were said to be one of the important culprits. As a mixed oxytocin/vasopressin V1a receptor antagonist, atosiban was identi ed to reduce uterine contractility and improve IVF success [9][10], with inconsistent conclusions [14,19]. So, our study was conducted to discover the potential effect of atosiban in the pregnancy outcome of IVF-ET.…”

Section: Discussionmentioning

confidence: 99%

“…As a mixed oxytocin/vasopressin V1a receptor antagonist, atosiban was used to reduce uterine contractility and improve IVF success by interfering with the oxytocin/PGF2a system with minimal side effects [9][10]. In 2007, Pierzynski et al [11][12] reported the safety and effectiveness of atosiban in the IVF-ET.…”

Section: Introductionmentioning

confidence: 99%

Atosiban application in fresh embryo transfer cycle is effective for women undergoing repeated embryo implantation failures, especially for advanced-age obese patients

Lin

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives To understand the effect of atosiban in pregnancy outcomes in the fresh embryo transfer (ET). Methods 689 cases (using atosiban) and 1377 age and embryo transfer cycle-matched controls were collected from the January 2016 to May 2022 to perform the fresh IVF-ET cycle. The essential characteristics and pregnancy outcomes including clinical pregnancy, ectopic pregnancy, abortion and live birth were analyzed. Conditional logistic regression analysis and subgroup analysis were performed. Results In the whole samples, atosiban had no effects in the pregnancy outcomes. Subgroup analyses suggested that atosiban could improve the clinical pregnancy in more than 3 embryo transfer cycles (OR = 1.667, 95%CI = 1.108–2.509, P = 0.014). Moreover, the improvement of clinical pregnancy was mainly present in the advanced-age women (Age ≥ 35 years: OR = 1.851, 95%CI = 1.136–3.014, P = 0.013), obesity (BMI ≥ 24 kg/m2: OR = 2.550, 95%CI = 1.105–5.883, P = 0.028) and cleavage stage embryo (D3 embryo: OR = 1.721, 95%CI = 1.098–2.696, P = 0.018) among the repeated implantation failures (RIF). Atosiban could also improve the live birth for the obese women. Further, in the RIF, atosiban application was strongly recommended for the advanced-age infertility women, who also had the risk of obesity (Clinical pregnancy: OR = 3.342, 95%CI = 1.249–8.942, P = 0.016; Live birth: OR = 12.123, 95%CI = 2.191–67.089, P = 0.004) and transferred the cleavage stage embryo (D3 embryo: OR = 1.922, 95%CI = 1.135–3.255, P = 0.015). Conclusion Atosiban in fresh ET cycle could improve the clinical pregnancy rate and live birth for the advanced-age and obese women undergoing more than 3 embryo transfer cycles, especially when transplanting the cleavage stage embryo.

show abstract

“…The application of atosiban in IVF that may decrease uterine peristalsis to improve uterine receptivity during ET was first reported by Pierzynski et al in 2007 (20). In recent years, many clinical studies evaluating more outcome measures, such as clinical pregnancy, live birth, miscarriage, multiple pregnancy, implantation and ectopic pregnancy rates has been conducted on this issue (21)(22)(23)(24)(25)(26). The effectiveness of atosiban intervention in IVF-ET still remained controversial and ambiguous based on the published evidence.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundRepeated embryo implantation failure (RIF) posed a significant challenge in assisted reproduction. Evidence of its therapeutic effectiveness including atosiban used around embryo transfer to improve pregnancy outcomes in RIF patients undergoing in vitro fertilization-embryo transfer (IVF-ET) remained inconsistent. This study aimed to explore the efficacy of atosiban on pregnancy outcomes of patients with RIF who received IVF-ET. MethodsThe research was designed using the PICOS format. A systematic search of four English databases, PubMed, EMBASE, Web of Science, Cochrane Library, and one Chinse database, China National Knowledge Infrastructure (CNKI) was conducted. The time range was from inception to December 10, 2022. Then trials comparing the efficacy of atosiban and control group on pregnancy outcomes in RIF patients who receive IVF-ET were included. Subgroup analysis and sensitivity analysis were performed to reduce the influence of heterogeneity between included studies. Risk ratio (RR) and 95% confidence interval (CI) were calculated. The main outcome measure was clinical pregnancy rate (CPR). For the analyses, StataMP 17.0 (Stata Corporation, USA) was used.ResultsTwo prospective randomized controlled trials (RCTs), one prospective cohort study and four retrospective cohort studies were included. Our results showed that atosiban was associated with higher clinical pregnancy rate (RR=1.54, 95% CI: 1.365–1.735, P < 0.001, I2 = 0.0%). The results of subgroup analysis based on study types (prospective randomized controlled clinical trial, retrospective cohort study and prospective cohort study) showed that in all types of studies, CPR of atosiban group was significantly higher than controlled group. The results of subgroup analysis based upon the diagnostic criteria of number of previous embryo transfer failures showed that the intervention of atosiban improved the CPR whether in participants with 2 previous ET failures or in participants with 3 previous ET failures. Nevertheless, the incidence of ectopic pregnancy, multiple pregnancy, and miscarriages were not significantly different between the case and control groups.ConclusionFor women who are undergoing IVF-ET and have experienced repeated embryo implantation failure, atosiban may be an important factor in enhancing pregnancy outcomes. To confirm this conclusion, more thorough, prospective randomized controlled studies of sizable sample sizes with well design are required.

show abstract

A prospective case–control trial to evaluate and compare the efficacy and safety of atosiban versus placebo in In vitro Fertilization-embryo transfer program

Cited by 6 publications

References 12 publications

Effect of administration of atosiban at day of embryo transfer on in-vitro fertilization out come

Effect of administration of atosiban at day of embryo transfer on in-vitro fertilization out come

Atosiban application in fresh embryo transfer cycle is effective for women undergoing repeated embryo implantation failures, especially for advanced-age obese patients

Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis

Contact Info

Product

Resources

About